Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Finished Goods (2025)

Crinetics Pharmaceuticals has reported Finished Goods over the past 1 years, most recently at $18000.0 for Q4 2025.

  • Quarterly results put Finished Goods at $18000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $18000.0 (changed N/A YoY), and the annual figure for FY2025 was $18000.0, changed.
  • Finished Goods for Q4 2025 was $18000.0 at Crinetics Pharmaceuticals.
  • Over the last five years, Finished Goods for CRNX hit a ceiling of $18000.0 in Q4 2025 and a floor of $18000.0 in Q4 2025.